Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial
Adriana Bastidas,Javier de la Serna,Mohamed El Idrissi,Lidia Oostvogels,Philippe Quittet,Javier López-Jiménez,Filiz Vural,David Pohlreich,Tsila Zuckerman,Nicolas C Issa,Gianluca Gaidano,Je-Jung Lee,Sunil Abhyankar,Carlos Solano,Jaime Perez de Oteyza,Michael J Satlin,Stefan Schwartz,Magda Campins,Alberto Rocci,Carlos Vallejo Llamas,Dong-Gun Lee,Sen Mui Tan,Anna M Johnston,Andrew Grigg,Michael J Boeckh,Laura Campora,Marta Lopez-Fauqued,Thomas C Heineman,Edward A Stadtmauer,Keith M Sullivan,ZOE-HSCT Study Group Collaborators,Aránzazu Alonso Alonso,Achilles Anagnostopoulos,Charalambos Andreadis,Maria Angelopoulou,Veli-Jukka Anttila,Mickael Aoun,Ibrahim Barista,Leanne Berkahn,Adrian J. C. Bloor,Raewyn Broady,Peter Brossart,Francis K. Buadi,Claude-Eric Bulabois,Guy Cantin,Claudia Cellini,Pranatharthi Haran Chandrasekar,Thomas Chauncey,Antonio Cuneo,Sanjeet Singh Dadwal,Michael Dickinson,HyeonSeok Eom,Albert Esquirol Sanfeliu,Christelle Ferra Coll,Phyllis R. Flomenberg,Ana Pilar González-Rodríguez,David J. Gottlieb,Sigal Grisariu,Andreas Guenther,Jonathan Gutman,Uwe Hahn,Werner J. Heinz,Inmaculada Heras,Takashi Ikeda,Isidro Jarque,Meinolf Karthaus,Tessa Kerre,Alexander Kiani,Andreas K. Klein,Grzegorz Kofla,Irina V. Kryuchkova,Ching-Yuan Kuo,John Kuruvilla,Aleksey Kuvshinov,Jae-Yong Kwak,Jae Hoon Lee,Stéphane Lepretre,Albert Kwok-Wai Lie,Alessandro Lucchesi,Johan Maertens,Erik W. A. Marijt,Carmen Martínez Muñoz,Mariagrazia Michieli,Samuel T Milliken,Noël Milpied,Jorge Monserrat Coll,Sherif Beniameen Mossad,John Murphy,María Belén Navarro Matilla,Jan Novak,Harold J. Olney,Raquel Oña Navarrete,María Jesús Pascual Cascón,Andy Peniket,Ganeva Penka,Beata Piątkowska-Jakubas,Marta Polo Zarzuela,Dimas Quiel,Scott D Rowley,Waleed Sabry,Tommi Mikael Salmi,Dominik L. D. Selleslag,Thomas C. Shea,Gerda Silling,Ulla Marjatta Sinisalo,Sang Kyun Sohn,Peter Staib,Jeff Szer,Koen Theunissen,Pervin Topcuoglu,Natalya G. Tyurina,Mikhail Uvarov,Fadilah S. Abdul Wahid,Lucrecia Yáñez San Segundo,Zeynep Arzu Yegin,Su-Peng Yeh,Sze-Fai Yip,Sung Soo Yoon,Jo-Anne H. Young,Pierre Zachée,Francesco Zaja,Maria de la Concepción Aláez Usón,James Bailey,Jacques-Olivier Bay,Norbert Blesing,Michael J. Boeckh,John Carter,Luca Castagna,June-Won Cheong,Ilseung Choi,Takaaki Chou,Graham Cohen,Terrance Comeau,Diane Coso,Natalia de las Heras Rodriguez,Maike de Wit,Jehan Dupuis,Gerlinde Egerer,Kazimierz Halaburda,Matthew C. Hall,Wen-Li Hwang,Takayuki Ishikawa,Kazuhiko Kakihana,Georgios Karianakis,Stefan Klein,Andrew McDonald,Arnd Nusch,Tomas Papajik,Oleg Rukavitsyn,Rik Schots,Anthony Schwarer,Edward A. Stadtmauer,Keith M. Sullivan,Kazutaka Sunami,Patrizia Tosi,Estil A. Vance,María Teresa Villaescusa de la Rosa,Renata Walewska,Po-Nan Wang,Pavel Zak
DOI: https://doi.org/10.1001/jama.2019.9053
IF: 11.816
2019-07-09
JAMA
Abstract:Importance: Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. Objective: To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. Design, setting, and participants: Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. Interventions: Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n = 922) or placebo (n = 924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. Main outcomes and measures: The primary end point was occurrence of confirmed herpes zoster cases. Results: Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P < .001), equivalent to 68.2% vaccine efficacy. Of 8 secondary end points, 3 showed significant reductions in incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR, 0.1; 95% CI, 0.00-0.78; P = .02) and of other prespecified herpes zoster-related complications (vaccine, n=3; placebo, n=13; IRR, 0.22; 95% CI, 0.04-0.81; P = .02) and in duration of severe worst herpes zoster-associated pain (vaccine, 892.0 days; placebo, 6275.0 days; hazard ratio, 0.62; 95% CI, 0.42-0.89; P = .01). Five secondary objectives were descriptive. Injection site reactions were recorded in 86% of vaccine and 10% of placebo recipients, of which pain was the most common, occurring in 84% of vaccine recipients (grade 3: 11%). Unsolicited and serious adverse events, potentially immune-mediated diseases, and underlying disease relapses were similar between groups at all time points. Conclusions and relevance: Among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine compared with placebo significantly reduced the incidence of herpes zoster over a median follow-up of 21 months. Trial registration: ClinicalTrials.gov Identifier: NCT01610414.